DDR1 and nonpapillary renal cell carcinoma: Because of the above information, we analyzed how DDR gene mutations affect the efficacy of immunogenicity therapy in ccRCC patients from the aspects of the tumor genome, tumor immunogenicity, and the tumor immune microenvironment.